Last updated: October 5, 2026
MYOVIEW is a technetium Tc 99m tetrofosmin radiopharmaceutical kit used for myocardial perfusion imaging. GE HealthCare markets the product in the United States under NDA 020687. Its commercial profile is mature and largely defensive: demand is tied to SPECT cardiac-imaging volumes, nuclear-medicine infrastructure, reimbursement, and reliable molybdenum-99/technetium-99m supply rather than to new clinical differentiation. GE HealthCare does not publicly report MYOVIEW revenue separately, so the product’s financial trajectory must be assessed through market drivers and company-level disclosures.
What is MYOVIEW and how is it used?
MYOVIEW is a nonradioactive kit containing tetrofosmin. A healthcare provider reconstitutes the kit with technetium Tc 99m pertechnetate before administration. The resulting radiopharmaceutical is used with single-photon emission computed tomography to image myocardial perfusion at rest and during stress testing.
The FDA-approved label covers:
- Detection of coronary artery disease.
- Assessment of myocardial perfusion.
- Evaluation of left ventricular function when gated SPECT imaging is performed.
- Rest and stress imaging protocols.
The product is supplied as a multi-dose kit containing vials of tetrofosmin and excipients. The radiolabeled product has a short effective commercial life because technetium-99m decays rapidly. That characteristic makes distribution, radiopharmacy preparation, and scheduling central to the product’s economics. [1]
MYOVIEW competes primarily with technetium Tc 99m sestamibi products, including CARDIOLITE and generic sestamibi offerings. It also competes indirectly with thallium-201 SPECT and positron emission tomography agents used in cardiac imaging.
What is the FDA regulatory status of MYOVIEW?
MYOVIEW was approved in the United States under NDA 020687. The product is a diagnostic radiopharmaceutical rather than a therapeutic medicine. Its regulatory status is therefore driven by the approved kit formulation, manufacturing controls, radiolabeling instructions, sterility, stability, and quality controls.
| Regulatory attribute |
MYOVIEW status |
| Active ingredient |
Tetrofosmin, labeled with technetium Tc 99m |
| FDA application |
NDA 020687 |
| Dosage form |
Kit for preparation of technetium Tc 99m tetrofosmin injection |
| Primary use |
Myocardial perfusion imaging |
| Administration |
Intravenous |
| Regulatory category |
Diagnostic radiopharmaceutical |
| Marketing company |
GE HealthCare entities |
| Approval era |
1990s |
| Product-specific revenue disclosure |
Not separately reported |
The product’s regulatory value comes from an established approval, manufacturing history, and integration into nuclear cardiology workflows. A competitor must demonstrate pharmaceutical equivalence and satisfy the FDA’s requirements for a radiopharmaceutical kit, including sterility and product quality.
What patents protect MYOVIEW?
MYOVIEW is a mature product with limited apparent dependence on currently enforceable composition-of-matter patent protection. Its commercial protection is more likely to arise from manufacturing know-how, regulatory history, customer relationships, supply reliability, and operational execution than from a long-lived patent monopoly.
The relevant protection categories are:
| Protection category |
Commercial relevance |
| Tetrofosmin composition patents |
Likely expired or commercially weak because the product was developed and approved decades ago |
| Kit formulation patents |
Any historical claims are likely to have expired or provide limited current exclusivity |
| Method-of-use patents |
Cardiac perfusion use is mature and unlikely to create meaningful current exclusivity |
| Manufacturing processes |
Can remain commercially important as confidential know-how even without patent exclusivity |
| FDA approval |
Creates a regulatory entry requirement but does not itself block all competing products |
| Trademark |
MYOVIEW branding supports recognition but does not prevent generic competition |
The FDA Orange Book should be reviewed for current patent listings associated with NDA 020687 before making a litigation or launch decision. Publicly available product information does not indicate that MYOVIEW’s current commercial position depends on an unexpired foundational patent. [2]
What formulation patents protect MYOVIEW?
The formulation includes tetrofosmin and excipients in a sterile kit format designed for later radiolabeling. The important technical barriers are consistent reconstitution, radiochemical purity, stability, sterility, and reliable performance after preparation with technetium pertechnetate.
Even when formulation patents expire, the manufacturing process can remain difficult to duplicate. Radiopharmaceutical products require validated production facilities, specialized release testing, short distribution cycles, and compliance with drug and radiation-safety requirements.
When does MYOVIEW lose exclusivity?
MYOVIEW’s principal patent-based exclusivity appears to have expired or materially eroded. The product was approved in the 1990s, and its commercial protection today is not comparable to that of a recently launched small molecule.
There is no meaningful pediatric exclusivity or new chemical entity exclusivity remaining. Any historical five-year NCE period would have expired long ago. The product also does not benefit from biologic exclusivity because it is a small-molecule diagnostic radiopharmaceutical.
The practical exclusivity timeline is therefore:
| Period |
Commercial position |
| 1990s |
FDA approval and branded market establishment |
| 2000s |
Mature cardiac SPECT product with established clinical use |
| 2010s |
Increasing competition from generic and alternative technetium-based products |
| 2020s |
Mature branded product; value concentrated in supply, manufacturing, and distribution |
Are there MYOVIEW Paragraph IV challenges or generic launch risks?
A traditional Paragraph IV challenge would require an ANDA applicant to certify that listed patents are invalid, unenforceable, or not infringed. The commercial importance of such a challenge depends on whether the Orange Book contains live patents associated with the product.
For MYOVIEW, the principal generic-launch risks are regulatory and operational rather than patent-driven:
- Establishing pharmaceutical equivalence to the approved kit.
- Demonstrating sterility and acceptable radiochemical purity.
- Securing reliable technetium-99m supply.
- Building a radiopharmacy and hospital distribution network.
- Reaching sufficient scale before product decay and inventory losses erode margins.
Generic competition can enter through products based on the same active moiety or through alternative technetium-based myocardial perfusion agents. The existence of a competing product does not automatically require a direct MYOVIEW patent challenge if the competitor follows an approval pathway that does not infringe listed claims.
No widely publicized, product-defining MYOVIEW Paragraph IV litigation or settlement agreement is central to the current market narrative. The absence of prominent litigation is consistent with a mature product whose core intellectual-property barriers have weakened.
How strong is the MYOVIEW patent estate?
MYOVIEW has a weak-to-moderate current patent estate and a stronger operational moat.
| Factor |
Assessment |
| Composition-of-matter protection |
Weak because of product age |
| Formulation protection |
Limited current value |
| Method-of-use protection |
Limited for established myocardial perfusion use |
| Manufacturing know-how |
Meaningful |
| Regulatory history |
Meaningful |
| Supply-chain capability |
Highly meaningful |
| Brand recognition |
Moderate |
| Switching costs |
Moderate at institutional level |
The strongest barriers are the need for validated sterile production, access to radionuclide supply, nuclear pharmacy logistics, and hospital procurement acceptance. These barriers can delay entry, but they do not create patent-style exclusivity.
What market forces determine MYOVIEW demand?
MYOVIEW demand tracks the volume of myocardial perfusion studies rather than prescription growth. The main drivers are:
SPECT installed base
SPECT remains widely deployed in hospitals, outpatient cardiology centers, and nuclear pharmacies. Existing equipment supports continued use of technetium-based agents without the capital investment required for broad PET conversion.
Cardiovascular disease burden
Coronary artery disease remains a major source of diagnostic imaging demand. Aging populations and chronic cardiovascular risk factors support baseline utilization, although payer controls and clinical guideline changes constrain growth.
Reimbursement
U.S. reimbursement from Medicare and commercial payers affects procedure volume, site-of-care economics, and hospital willingness to maintain nuclear cardiology services. Changes in physician payment, prior authorization, and bundled-care models can pressure radiopharmaceutical utilization. CMS payment policies are therefore more important to MYOVIEW demand than consumer marketing. [3]
Technetium-99m supply
MYOVIEW depends on a stable supply of technetium-99m, which is generated from molybdenum-99. Reactor outages, transportation disruptions, generator shortages, and geopolitical constraints can affect supply and create substitution pressure among radiopharmaceutical providers. The FDA and nuclear-medicine organizations have repeatedly identified isotope supply as a sector-wide operational issue. [4]
PET substitution
PET myocardial perfusion imaging can provide higher spatial and temporal resolution in certain settings. Wider PET adoption would pressure SPECT volumes, but the higher cost of PET infrastructure and limited availability of cardiac PET systems constrain rapid substitution.
How does MYOVIEW compare with CARDIOLITE and other cardiac agents?
MYOVIEW competes directly with technetium Tc 99m sestamibi products and indirectly with PET agents.
| Product category |
Active imaging agent |
Main advantage |
Main constraint |
| MYOVIEW |
Tc 99m tetrofosmin |
Established SPECT workflow and clinical familiarity |
Mature market and generic pressure |
| CARDIOLITE and generics |
Tc 99m sestamibi |
Broad adoption and multiple suppliers |
Competition and isotope dependence |
| Thallium-201 |
Tl-201 |
Established historical use |
Higher radiation burden and longer imaging protocols |
| Cardiac PET agents |
Various PET tracers |
Potentially higher diagnostic performance |
PET equipment, isotope, and reimbursement requirements |
Product selection is influenced by local formulary contracts, radiopharmacy availability, image quality, protocol preference, and price. No single agent has eliminated technetium-based SPECT from routine cardiac imaging.
What is MYOVIEW’s financial trajectory?
MYOVIEW is likely a stable-to-declining mature-product asset rather than a growth engine. GE HealthCare does not disclose MYOVIEW revenue, gross margin, unit volume, or operating profit as a separate reporting line. The company reports at segment level, including Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics. MYOVIEW is economically embedded within the Pharmaceutical Diagnostics portfolio rather than reported as a standalone business. [5]
The likely trajectory has four components:
- Volume: broadly stable in established SPECT markets, with gradual pressure from PET and utilization controls.
- Price: constrained by institutional contracting and generic alternatives.
- Margin: supported by manufacturing scale and established processes, but exposed to isotope, labor, quality, and distribution costs.
- Cash generation: potentially attractive because development costs are low, but limited by mature-market pricing and supply-chain requirements.
The product’s financial value is therefore portfolio-based. MYOVIEW can contribute recurring revenue and customer retention without requiring major clinical-development investment. Its value is lower than that of a protected growth product because competitors can target the same diagnostic indication with alternative kits or imaging agents.
What licensing deals affect MYOVIEW?
No major recent licensing transaction is publicly associated with MYOVIEW as a standalone asset. The product’s historical commercial development occurred within the broader radiopharmaceutical businesses that preceded GE HealthCare’s current structure.
The relevant strategic issue is ownership and portfolio continuity. GE HealthCare separated from General Electric in 2023, leaving GE HealthCare as an independent public company with Pharmaceutical Diagnostics operations. That reorganization changed corporate reporting but did not alter the established clinical role of MYOVIEW. [5]
What litigation and settlement issues affect MYOVIEW?
No major current patent litigation or settlement appears to define MYOVIEW’s market access. The principal legal exposure is more likely to arise from:
- Product liability and labeling claims.
- Good manufacturing practice enforcement.
- Supply and distribution contracts.
- ANDA litigation if a competitor identifies live Orange Book-listed patents.
- Quality failures involving sterility or radiochemical purity.
For investment analysis, the absence of headline patent litigation should not be interpreted as evidence of strong exclusivity. It more likely reflects the age of the product and the limited value of litigating an old diagnostic formulation.
What generic entry scenarios exist for MYOVIEW?
Three entry scenarios are commercially plausible.
Direct kit competition
A competitor launches a tetrofosmin kit or equivalent radiolabeled product after satisfying FDA requirements. This would create the clearest price pressure.
Cross-product substitution
Hospitals shift from MYOVIEW to sestamibi or another SPECT agent based on price, availability, or contracting. This can occur without a direct generic version of tetrofosmin.
Modality substitution
Cardiac PET gains share in high-volume centers, reducing SPECT demand. This scenario is slower because it requires PET equipment, trained staff, tracer availability, and favorable reimbursement.
The most probable near-term risk is cross-product substitution combined with institutional price pressure, not an abrupt patent-driven generic cliff.
What geographic markets support MYOVIEW?
The United States remains strategically important because of its large installed base of cardiac imaging systems and established reimbursement infrastructure. European and other developed markets also support technetium-based myocardial perfusion imaging, but national reimbursement, hospital procurement, radiopharmacy infrastructure, and product registrations differ.
International performance depends on:
- Local marketing authorization.
- National procurement systems.
- Generator and isotope availability.
- Radiopharmacy density.
- Cardiology referral patterns.
- Reimbursement for SPECT procedures.
Emerging markets may offer procedural growth but present greater supply-chain and regulatory complexity.
Key Takeaways
- MYOVIEW is a mature technetium Tc 99m tetrofosmin SPECT product marketed by GE HealthCare.
- Its current value rests more on regulatory history, manufacturing capability, supply reliability, and customer integration than on active patent exclusivity.
- Product-level revenue and profit are not separately disclosed.
- Demand is linked to myocardial perfusion SPECT volumes, reimbursement, installed equipment, and technetium-99m availability.
- The principal competitive threats are generic or alternative SPECT agents, followed by gradual cardiac PET substitution.
- No major current Paragraph IV dispute, licensing transaction, or patent settlement publicly defines MYOVIEW’s market.
- The likely financial profile is recurring but mature revenue, with limited volume growth and ongoing price pressure.
FAQs
Is MYOVIEW a generic drug or a branded radiopharmaceutical?
MYOVIEW is a branded radiopharmaceutical kit. It competes with other cardiac-imaging agents and potentially with equivalent tetrofosmin products, but its regulatory pathway differs from that of a conventional oral generic.
Does MYOVIEW require technetium-99m for administration?
Yes. The kit is reconstituted with technetium Tc 99m pertechnetate to produce the injectable imaging agent.
Is MYOVIEW protected by a new chemical entity exclusivity period?
No. Any original new chemical entity exclusivity would have expired decades ago because the product was approved in the 1990s.
Can hospitals switch from MYOVIEW to CARDIOLITE?
Yes. Hospitals can select among clinically appropriate myocardial perfusion agents based on formulary decisions, contracting, radiopharmacy supply, physician preference, and reimbursement.
Is MYOVIEW revenue reported by GE HealthCare?
No. GE HealthCare reports business results at segment and portfolio levels rather than disclosing MYOVIEW revenue, units, or profit separately.
References
- U.S. Food and Drug Administration. (n.d.). MYOVIEW kit for the preparation of technetium Tc 99m tetrofosmin injection: Prescribing information.
- U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.
- Centers for Medicare & Medicaid Services. (2024). Medicare physician fee schedule and outpatient payment policies.
- U.S. Food and Drug Administration. (n.d.). Medical isotope supply and radiopharmaceutical information.
- GE HealthCare Technologies Inc. (2024). Annual report and Form 10-K.
